Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for primary IgA nephropathy (ChiCTR2500103859)
ChiCTR2500103859Phase 4Recruiting
- Sponsor
- Zhongshan Hospital Affiliated to Fudan University Qingpu Branch
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in IgA nephropathy (IgAN) comparing Dapagliflozin 10 mg/day with Placebo 10 mg/day (2 arms). Primary endpoints: Urine protein, Renal function and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2500103859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103859.